{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T09:32:16Z","timestamp":1781775136273,"version":"3.54.5"},"reference-count":15,"publisher":"BMJ","issue":"4","license":[{"start":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T00:00:00Z","timestamp":1777507200000},"content-version":"unspecified","delay-in-days":29,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004917","name":"Cancer Prevention and Research Institute of Texas","doi-asserted-by":"publisher","award":["RP190360"],"award-info":[{"award-number":["RP190360"]}],"id":[{"id":"10.13039\/100004917","id-type":"DOI","asserted-by":"publisher"}]},{"name":"STrategic Research Initiative DEvelopment (STRIDE) program at The University of Texas MD Anderson Cancer Center","award":["Program for TCR-based Therapeutics (ProTCT)"],"award-info":[{"award-number":["Program for TCR-based Therapeutics (ProTCT)"]}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Immunother Cancer"],"accepted":{"date-parts":[[2026,4,9]]},"published-print":{"date-parts":[[2026,4]]},"abstract":"<jats:p>Clinical trials of adoptive cellular therapy demonstrate that a key characteristic associated with durable responses is in vivo expansion and persistence of transferred T cells. Strategies to develop a less differentiated, stem\/memory population in the infusion product and peri-infusional regimens to promote the maintenance of desired T cell states following adoptive transfer would be desirable. Endogenous T cell therapy studies have routinely achieved memory T cells enriched for expression of interleukin (IL)-7 receptor; to eliminate the conventional requirement for immunosuppressive lymphodepletion and its attendant life-threatening toxicities, we performed the first-in-human use of IL-7 in combination with adoptively transferred antigen-specific memory CD8 T cells in a patient with refractory metastatic uveal melanoma. Single-cell immune repertoire profiling of serial peripheral blood sampling revealed substantial in vivo proliferation and expansion of a stem cell memory population in the endogenous T cell therapy product that achieved a &gt;79% predominance of total circulating T cells by 3 weeks post-infusion in this non-lymphodepleted recipient. Although the patient\u2019s disease ultimately progressed, these findings demonstrate safety and proof of concept for an IL-7 treatment regimen for expansion of adoptively transferred T cells in vivo and induced memory differentiation in a heavily pretreated patient with refractory solid malignancy.<\/jats:p>","DOI":"10.1136\/jitc-2026-014822","type":"journal-article","created":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T15:30:12Z","timestamp":1777563012000},"page":"e014822","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":1,"title":["First-in-human use of recombinant IL-7 to potentiate antigen-specific T cell therapy: a single patient case study"],"prefix":"10.1136","volume":"14","clinical-trial-number":[{"clinical-trial-number":"nct03068624","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Casey","family":"Bermack","sequence":"first","affiliation":[{"name":"Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0681-3948","authenticated-orcid":false,"given":"Shailbala","family":"Singh","sequence":"additional","affiliation":[{"name":"Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guangsheng","family":"Pei","sequence":"additional","affiliation":[{"name":"Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sapna P","family":"Patel","sequence":"additional","affiliation":[{"name":"Departments of Medicine & Ophthalmology, University of Colorado, Aurora, Colorado, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linghua","family":"Wang","sequence":"additional","affiliation":[{"name":"Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA"},{"name":"Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cassian","family":"Yee","sequence":"additional","affiliation":[{"name":"Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA"},{"name":"Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA"},{"name":"Department of Immunology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2026,4,30]]},"reference":[{"key":"2026043008300887000_14.4.e014822.1","doi-asserted-by":"crossref","unstructured":"Hasan F , Yee C . Non-engineered adoptive t cell therapy. In: Butterfield L , Kaufman HL , Marincola FM , eds. Cancer immunotherapy principles and practice. Springer Publishing, 2021.","DOI":"10.1891\/9780826137432.0025"},{"key":"2026043008300887000_14.4.e014822.2","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.coi.2018.04.007","article-title":"Adoptive T cell therapy: points to consider","volume":"51","author":"Yee","year":"2018","journal-title":"Curr Opin Immunol"},{"key":"2026043008300887000_14.4.e014822.3","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.175.4.2261"},{"key":"2026043008300887000_14.4.e014822.4","doi-asserted-by":"crossref","unstructured":"Chapuis AG , Desmarais C , Emerson R , et al . Tracking the fate and origin of clinically relevant adoptively transferred CD8 + T cells in vivo. Sci Immunol 2017;2. doi:10.1126\/sciimmunol.aal2568","DOI":"10.1126\/sciimmunol.aal2568"},{"key":"2026043008300887000_14.4.e014822.5","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3004916","article-title":"Transferred WT1-reactive CD8+ T cells can mediate antileukemic activity and persist in post-transplant patients","volume":"5","author":"Chapuis","year":"2013","journal-title":"Sci Transl Med"},{"key":"2026043008300887000_14.4.e014822.6","doi-asserted-by":"crossref","first-page":"3787","DOI":"10.1200\/JCO.2015.65.5142","article-title":"T-Cell Therapy Using Interleukin-21-Primed Cytotoxic T-Cell Lymphocytes Combined With Cytotoxic T-Cell Lymphocyte Antigen-4 Blockade Results in Long-Term Cell Persistence and Durable Tumor Regression","volume":"34","author":"Chapuis","year":"2016","journal-title":"J Clin Oncol"},{"key":"2026043008300887000_14.4.e014822.7","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-09-1303"},{"key":"2026043008300887000_14.4.e014822.8","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1158\/1078-0432.CCR-24-1728","article-title":"A Phase II Open-Label, Randomized Clinical Trial of Atezolizumab with or without Human Recombinant IL-7 (CYT107) in Advanced Urothelial Cancer","volume":"31","author":"Sweis","year":"2025","journal-title":"Clin Cancer Res"},{"key":"2026043008300887000_14.4.e014822.9","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-002903","article-title":"IL-7 expands lymphocyte populations and enhances immune responses to sipuleucel-T in patients with metastatic castration-resistant prostate cancer (mCRPC)","volume":"9","author":"Pachynski","year":"2021","journal-title":"J Immunother Cancer"},{"key":"2026043008300887000_14.4.e014822.10","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-022-30860-0","article-title":"A long-acting interleukin-7, rhIL-7-hyFc, enhances CAR T cell expansion, persistence, and anti-tumor activity","volume":"13","author":"Kim","year":"2022","journal-title":"Nat Commun"},{"key":"2026043008300887000_14.4.e014822.11","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.189150","article-title":"A randomized, double-blind, placebo-controlled trial of IL-7 in critically ill patients with COVID-19","volume":"10","author":"Shankar-Hari","year":"2025","journal-title":"JCI Insight"},{"key":"2026043008300887000_14.4.e014822.12","doi-asserted-by":"publisher","DOI":"10.1172\/JCI38052"},{"key":"2026043008300887000_14.4.e014822.13","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciw065"},{"key":"2026043008300887000_14.4.e014822.14","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-06-437236"},{"key":"2026043008300887000_14.4.e014822.15","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-17-0051"}],"container-title":["Journal for ImmunoTherapy of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jitc-2026-014822","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T15:30:15Z","timestamp":1777563015000},"score":1,"resource":{"primary":{"URL":"https:\/\/jitc.bmj.com\/lookup\/doi\/10.1136\/jitc-2026-014822"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":15,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2026,4,30]]},"published-print":{"date-parts":[[2026,4]]}},"alternative-id":["10.1136\/jitc-2026-014822"],"URL":"https:\/\/doi.org\/10.1136\/jitc-2026-014822","relation":{},"ISSN":["2051-1426"],"issn-type":[{"value":"2051-1426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4]]}}}